Zimbabwe has rejected a substantial US health deal valued at $367m (£272m) spanning five years due to the United States' insistence on confidential information.
This move became public after a internal memorandum from December was disclosed, indicating that Head of State Emmerson Mnangagwa deemed the agreement was "skewed".
An official spokesman has since stated that the US was requesting genetic material for research and commercial purposes but refused to guarantee the benefits from future vaccines.
"We must now begin the challenging and unfortunate task of ending our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had furnished over $1.9bn in health funding to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has called for more dialogue to reach a agreement agreeable to all parties so the country's vital HIV treatment initiative can proceed.
Wider Context
This development follows a similar case in neighbouring Kenya, where a high court suspended a similar health funding agreement after concerns were filed about the security of Kenyans' health data.
Since resuming the presidency last year, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
USAID had administered aid for the American government, but Trump stated its spending was "inefficient" and his administration was seeking direct bilateral deals to boost openness and responsibility.
According to reports, Sixteen African countries have to date agreed to these new agreements, representing over $18.3bn in new funding.
Details of the Rejected Deal
This assistance for Zimbabwe was intended to gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this partnership might have yielded significant advantages for Zimbabwean communities, particularly the 1.2 million presently on HIV treatment via US-supported programmes," Tremont added.
However, official spokesman Nick Mangwana maintained the arrangement was "unfair".
"Our nation was requested to surrender its biological resources and data for a long time, without any equivalent assurance of access to any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that provided information," his statement read.
"In essence, our country would provide the raw materials for medical research with no assurance that the final treatments would be accessible to our population should a new disease outbreak arise."
Sovereignty and International Frameworks
He also said that the American exit from the global health body and its push of one-on-one deals were undermining systems already established via the international organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme designed to deal with future global health emergencies.
"This system is designed to ensure that when a country provides its samples, the resulting advantages – such as vaccines and treatments – are distributed fairly, not commercialised solely by those with the funds to develop them."
The government's concerns over the US deal "are not meant as anti-American sentiment," he added.
"We welcome further dialogue with our American counterparts on how future collaboration could be designed in a manner that respects the independence and interests of each country."
Medical Community Reaction
A leading public health body expressed it understood the official position, but urged that negotiations must proceed since much of the nation's Aids initiatives were funded by foreign aid.
"Where technical issues exist, such as those relating to information security or agreement terms, these can often be addressed through technical clarification and mutually agreed protections," it commented.
The halted deal highlights the complex challenges between accepting vital international aid and safeguarding local interests in an ever more interconnected world.